Welcome to the DarkDaily.com Special Reports Library
Created and maintained as a service to the Clinical and Anatomic Pathology Industry, this unique library program provides laboratory executives with:
- An important and useful resource for knowledge and information about the management of labs
- A one of a kind, in-depth intelligence report on Lab Quality, Lab Management, Collections and Billing and much more
New Special Reports are added frequently, so please check back!
What Hospital and Health Network Labs Must Know to Comply with PAMA Private Payer Price Reporting
This comprehensive workshop is designed to help hospital CEOs, CFOs, their laboratory administrators, and others tasked with data reporting and other requirements of PAMA to fulfill this federal law, with the data reported used to calculate an updated Clinical Laboratory Fee Schedule expected to go into effect Jan. 1, 2021.
“What Hospital and Health Network Clinical Laboratories Must Know to Comply with PAMA Private Payer Price Reporting” is based on federal guidance, enhanced by the expertise of health law practice attorneys, health system leaders who are already reporting data, and other experts. This series of 8 videos comes with a comprehensive companion PDF handbook that supplements the videos, and helps weave together the maze of federal guidance into a wealth of easily accessible resources.
This program package is an ideal educational and training tool for each team member tasked with the PAMA data reporting project, as well as the hospital, health system, and medical laboratory leader who must certify their organization’s data to CMS in a timely manner.
Intelligence Assessment of Today’s Clinical Laboratory Industry
We are at a historic crossroads, both in healthcare and in laboratory medicine. We’re seeing a pace of change and transformation that’s unprecedented since World War II. Successful labs require awareness and a keen understanding of the emerging healthcare marketplace.
Learn how your medical lab can survive the transition from volume- to value-based healthcare, by identifying opportunities to deliver recognized, unquestioned value to physicians, patients, parent hospitals, health systems and payers.
The Growing Role of Quality Management Systems In Clinical Laboratory Accreditation and Licensure
CLIA inspections are growing tougher every year. It’s the same story with Medicare accreditation of clinical laboratories. Requirements are tightening. Onsite lab inspections and assessments are becoming more rigorous.
Get a full understanding of how and why the use of a Quality Management System (QMS) is such a powerful way to put your laboratory at full compliance, ready for surprise inspections that result in a “no deficiency” outcome.
Latest E-Briefings
Two Healthcare Attorneys Discuss Remedies for Medical Laboratories Facing Financial Distress Due to COVID-19
Though lenders and landlords may be willing to renegotiate terms, communication is key, the lawyers suggest COVID-19 has vastly increased demand for clinical laboratory testing. But at many labs, the pandemic has caused much damage to the bottom line. Due to numerous...
UCSF Researchers Discover COVID-19 Coronavirus Evolved to Grow Tentacles and Use Them to Infect Other Cells!
Study scientists identified several currently available drugs that could inhibit growth of these “streaming filaments,” which infected cells use to go after non-infected cells Like a scene from a bad horror movie, scientists have discovered that SARS-CoV-2, the...
Despite the Coronavirus Pandemic, Medicare Officials Continue Push for Price Transparency by Pressuring Hospitals to Disclose Rates Negotiated with Private Payers
Clinical laboratories are advised to continue developing methods for making prices for procedures available to the general public Even as an effective treatment for COVID-19 continues to elude federal healthcare agencies, Medicare officials are pressing ahead with...
Abbott Lab’s ID NOW COVID-19 Rapid Molecular Test Continues to Face Scrutiny over ‘False Negatives’
Though the test initially drew ‘raves’ from Trump administration, the FDA now suggests negative results should be confirmed with an additional ‘high-sensitivity authorized SARS-CoV-2 molecular test’ This spring, as the United States attempted to jump-start a national...